You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Multiple myeloma at high risk for disease recurrence.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Jul 13, 2023

Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)

Active, not recruiting
  • Multiple Myeloma
  • High-Risk Cancer
  • Bortezomib following nonmyeloablative allogeneic transplant
  • Montreal, Quebec, Canada
    HĂ´pital Maisonneuve-Rosemont
Aug 22, 2022

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Nov 17, 2023

Smoldering Multiple Myeloma Trial (Selinexor)

Not yet recruiting
  • Smoldering Multiple Myeloma
  • (no location specified)
Oct 27, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • TG01
  • Oslo, Norway
    Oslo Myeloma Center
May 2, 2023

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Myeloma Multiple Trial in Orange, Nashville (Descartes 08)

Recruiting
  • Myeloma Multiple
  • Descartes 08
  • Orange, California
  • +1 more
Apr 4, 2022

High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 11, 2022

Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 8, 2023

Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)

Recruiting
  • Multiple Myeloma
  • Ixazomib plus low-dose lenalidomide
  • Ixazomib
  • Hangzhou, Zhejiang, China
    Yang Xu
Feb 9, 2023

Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

Recruiting
  • Multiple Myeloma
  • Autologous hematopoietic stem cell transplantation
  • C-CAR088
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 21, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma, Lymphoma Trial in Washington, Hackensack (Ipilimumab, Nivolumab)

Active, not recruiting
  • Multiple Myeloma
  • Lymphoma
  • Washington, District of Columbia
  • +1 more
Dec 2, 2021

Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
Nov 15, 2022

Multiple Myeloma, Cancer, Hematologic Cancer Trial in Cork (Discontinuation of maintenance treatment)

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Discontinuation of maintenance treatment
  • Cork, Ireland
    Cork University Hospital
May 10, 2023

Selinexor, Daratumumab and Dexamethasone in Chinese Multiple

Not yet recruiting
  • Multiple Myeloma at First Relapse
    • (no location specified)
    Sep 27, 2022

    Clinical Research of Drug Holiday Based on MRD Detection in GIST

    Recruiting
    • Gastrointestinal Stromal Tumors
      • Beijing, Beijing, China
        Peking University People's Hospital
      May 11, 2023

      High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

      Not yet recruiting
      • High-Risk de Novo Multiple Myeloma
      • Badalona, Spain
      • +9 more
      Apr 27, 2023

      Digital Droplet PCR in Early Period After Allo-HSCT to Predict

      Completed
      • Measurable Residual Disease
      • Digital Droplet PCR
      • Hangzhou, Zhejiang, China
        The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
      Aug 17, 2023

      Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

      Not yet recruiting
      • Triple Negative Breast Cancer
      • Residual Disease
      • (no location specified)
      Nov 15, 2023

      Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

      Not yet recruiting
      • Multiple Myeloma
      • Smoldering Multiple Myeloma
      • Ciltacabtagene Autoleucel
      • +2 more
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Mar 2, 2023

      Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

      Recruiting
      • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University
      Jan 4, 2023

      Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

      Not yet recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Adjuvant tislelizumab plus lenvatinib
      • Adjuvant tislelizumab
      • Nanning, China
        Jian-Hong Zhong
      Jun 11, 2023

      Multiple Myeloma Trial in Philadelphia (CART-19 cells)

      Terminated
      Has Results
      • Multiple Myeloma
      • CART-19 cells
      • Philadelphia, Pennsylvania
        Abramson Cancer Center of the University of Pennsylvania
      Jan 4, 2023